Doximity, Inc. (NASDAQ: DOCS) director Kira Scherer Wampler has finalized a transaction involving the sale of 9,000 shares of Class A Common Stock. Executed on May 7, 2026, the sale was valued at $234,540, based on a per-share price of $26.06. This particular movement of equity was handled automatically through a Rule 10b5-1 trading plan that Wampler had adopted back in November 2024.
The liquidation process involved several steps regarding the conversion of different share classes. Before the sale, Wampler exercised options to acquire 9,000 shares of Class B Common Stock at an exercise price of $1.54 per share. These options were tied to a grant from June 10, 2020, and were subject to a vesting period of 36 equal monthly installments following March 27, 2020, provided that Wampler maintained continuous service with the firm. Following this acquisition, the Class B Common Stock was converted into an equivalent amount of Class A Common Stock, as each Class B share carries the option to convert into one Class A share.
Post-transaction, Wampler's direct holdings in Doximity Class A Common Stock stand at 19,839 shares. Additionally, she maintains a position in derivative securities, holding 447,700 stock options. This insider activity takes place against a backdrop of significant price movement for the company; Doximity shares have seen a decline of 52% over the last six months. The stock is currently trading at $25.98, which sits near its 52-week low of $20.55.
Key Market Points
- Insider Equity Movement: The execution of Rule 10b5-1 plans by directors provides a structured mechanism for equity liquidation, though the timing occurs as the stock faces recent downward pressure in the broader healthcare technology market.
- Valuation Discrepancy: While shares have declined significantly, some analytical models suggest the current price may not reflect intrinsic value, citing a Fair Value estimate of $35.53 and high gross profit margins approaching 90%.
- Corporate Financial Position: Doximity maintains a balance sheet characterized by holding more cash than debt, a factor that impacts its stability within the technology sector.
Risks and Uncertainties
- Growth Visibility and Revenue Risk: Analysts have noted concerns regarding reduced visibility into revenue growth, specifically related to structural risks and potential fluctuations in pharmaceutical digital marketing budgets. This affects the healthcare services and advertising sectors.
- Leadership Transitions: The resignation of CFO Anna Bryson, who had been on medical leave, introduces a period of transition, with Siddharth Sitaram currently acting as the interim principal financial officer.
- AI-Related Market Shifts: While new products like ChatGPT for Clinicians aim to streamline administrative tasks, there are ongoing discussions regarding AI-related issues and their impact on long-term growth expectations.
Analyst Perspectives
The investment community remains divided on the stock's trajectory. Raymond James has maintained a Strong Buy rating with a $40.00 price target, following the introduction of OpenAI’s ChatGPT for Clinicians to aid physician workflows. Similarly, Leerink Partners recently increased its price target from $31 to $34 while maintaining an Outperform rating, arguing that the stock is undervalued despite growth and AI concerns.
Conversely, Truist Securities has adopted a more cautious stance, downgrading the stock from Buy to Hold and lowering its price target from $37 to $29. This downgrade was driven by limited clarity on pharmaceutical digital marketing spend and projections for fiscal year 2027 growth that fall below current consensus expectations.